Bright Health Gr Analyst Ratings
Bright Health Gr Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/30/2023 | -7.19% | Morgan Stanley | $160 → $8 | Maintains | Underweight |
| 08/14/2023 | 85.61% | RBC Capital | $13 → $16 | Maintains | Sector Perform |
| 06/30/2023 | 886.08% | Nephron Research | → $85 | Upgrades | Hold → Buy |
| 06/15/2023 | -7.19% | Barclays | $4 → $8 | Downgrades | Overweight → Underweight |
| 05/30/2023 | 50.81% | RBC Capital | $80 → $13 | Maintains | Sector Perform |
| 05/23/2023 | 1756.15% | Morgan Stanley | $12800 → $160 | Maintains | Underweight |
| 05/22/2023 | 148391.88% | Morgan Stanley | $160 → $12800 | Maintains | Underweight |
| 05/19/2023 | 1756.15% | Morgan Stanley | $2 → $160 | Maintains | Underweight |
| 12/13/2022 | -94.2% | Goldman Sachs | → $0.5 | Downgrades | Neutral → Sell |
| 11/16/2022 | -86.08% | Citigroup | $2.25 → $1.2 | Maintains | Neutral |
| 10/11/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 08/11/2022 | -65.2% | Piper Sandler | $5 → $3 | Maintains | Overweight |
| 05/12/2022 | -65.2% | Goldman Sachs | $3.5 → $3 | Maintains | Neutral |
| 03/29/2022 | -76.8% | JP Morgan | → $2 | Downgrades | Overweight → Neutral |
| 03/04/2022 | -65.2% | RBC Capital | $9 → $3 | Downgrades | Outperform → Sector Perform |
| 03/03/2022 | -76.8% | Morgan Stanley | $4 → $2 | Maintains | Underweight |
| 03/03/2022 | -59.4% | Goldman Sachs | $5 → $3.5 | Maintains | Neutral |
| 03/03/2022 | -53.6% | Barclays | $5.5 → $4 | Maintains | Overweight |
| 03/03/2022 | -42% | Piper Sandler | $10 → $5 | Maintains | Overweight |
| 01/07/2022 | -36.19% | Barclays | $9 → $5.5 | Maintains | Overweight |
| 12/17/2021 | -53.6% | Morgan Stanley | $5 → $4 | Downgrades | Equal-Weight → Underweight |
| 12/16/2021 | -53.6% | Morgan Stanley | $5 → $4 | Downgrades | Equal-Weight → Underweight |
| 12/14/2021 | -42% | Goldman Sachs | → $5 | Initiates Coverage On | → Neutral |
| 12/10/2021 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 11/12/2021 | -42% | Morgan Stanley | $13 → $5 | Downgrades | Overweight → Equal-Weight |
| 11/10/2021 | 39.21% | Barclays | $17 → $12 | Maintains | Overweight |
| 11/02/2021 | 4.41% | Cowen & Co. | $14 → $9 | Downgrades | Outperform → Market Perform |
| 09/10/2021 | 62.41% | Cowen & Co. | → $14 | Initiates Coverage On | → Outperform |
| 08/31/2021 | 50.81% | Morgan Stanley | $12 → $13 | Maintains | Overweight |
| 08/05/2021 | 39.21% | Morgan Stanley | $18 → $12 | Upgrades | Equal-Weight → Overweight |
| 08/04/2021 | 39.21% | Citigroup | $16 → $12 | Upgrades | Neutral → Buy |
| 07/19/2021 | 108.82% | Morgan Stanley | → $18 | Initiates Coverage On | → Equal-Weight |
| 07/19/2021 | 120.42% | JP Morgan | → $19 | Initiates Coverage On | → Neutral |
| 07/19/2021 | 74.01% | Wolfe Research | → $15 | Initiates Coverage On | → Peer Perform |
| 07/19/2021 | 317.63% | Goldman Sachs | → $36 | Initiates Coverage On | → Buy |
| 07/19/2021 | 155.22% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 07/19/2021 | 85.61% | Citigroup | → $16 | Initiates Coverage On | → Neutral |
| 07/19/2021 | 178.42% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月30日 | -7.19% | 摩根士丹利 | $160→$8 | 維護 | 體重不足 |
| 2023年08月14日 | 85.61% | 加拿大皇家銀行資本 | $13→$16 | 維護 | 行業表現 |
| 2023/06/30 | 886.08% | 腎單位研究 | →$85 | 升級 | 持有→購買 |
| 2023/06/15 | -7.19% | 巴克萊 | $4→$8 | 評級下調 | 增持→減持 |
| 2023年05月30日 | 50.81% | 加拿大皇家銀行資本 | $80→$13 | 維護 | 行業表現 |
| 2023年05月23日 | 1756.15% | 摩根士丹利 | $12800→$160 | 維護 | 體重不足 |
| 2023年05月22日 | 148391.88% | 摩根士丹利 | $160→$12800 | 維護 | 體重不足 |
| 2023年05月19日 | 1756.15% | 摩根士丹利 | $2→$160 | 維護 | 體重不足 |
| 2022年12月13日 | -94.2% | 高盛 | →$0.5 | 評級下調 | 中性→銷售 |
| 2022年11月16日 | -86.08% | 花旗集團 | $2.25→$1.2 | 維護 | 中性 |
| 2022年10月11日 | - | 摩根大通 | 評級下調 | 中性→減持 | |
| 2022年08月11日 | -65.2% | 派珀·桑德勒 | $5→$3 | 維護 | 超重 |
| 2022年05月12日 | -65.2% | 高盛 | $3.5→$3 | 維護 | 中性 |
| 03/29/2022 | -76.8% | 摩根大通 | →$2 | 評級下調 | 超重→中性 |
| 03/04/2022 | -65.2% | 加拿大皇家銀行資本 | $9→$3 | 評級下調 | 跑贏→板塊表現 |
| 03/03/2022 | -76.8% | 摩根士丹利 | $4→$2 | 維護 | 體重不足 |
| 03/03/2022 | -59.4% | 高盛 | $5→$3.5 | 維護 | 中性 |
| 03/03/2022 | -53.6% | 巴克萊 | $5.5→$4 | 維護 | 超重 |
| 03/03/2022 | -42% | 派珀·桑德勒 | $10→$5 | 維護 | 超重 |
| 01/07/2022 | -36.19% | 巴克萊 | $9→$5.5 | 維護 | 超重 |
| 2021/12/17 | -53.6% | 摩根士丹利 | $5→$4 | 評級下調 | 等重→減碼 |
| 12/16/2021 | -53.6% | 摩根士丹利 | $5→$4 | 評級下調 | 等重→減碼 |
| 2021年12月14日 | -42% | 高盛 | →$5 | 開始承保 | →中性 |
| 2021年12月10日 | - | 摩根大通 | 升級 | 中性→超重 | |
| 2021年11月12日 | -42% | 摩根士丹利 | $13→$5 | 評級下調 | 超重→等重 |
| 2021年11月10日 | 39.21% | 巴克萊 | $17→$12 | 維護 | 超重 |
| 11/02/2021 | 4.41% | 考恩公司 | $14→$9 | 評級下調 | 跑贏→市場表現 |
| 09/10/2021 | 62.41% | 考恩公司 | →$14 | 開始承保 | →跑贏大盤 |
| 2021/08/31 | 50.81% | 摩根士丹利 | $12→$13 | 維護 | 超重 |
| 08/05/2021 | 39.21% | 摩根士丹利 | $18→$12 | 升級 | 等重→超重 |
| 08/04/2021 | 39.21% | 花旗集團 | $16→$12 | 升級 | 中性→購買 |
| 07/19/2021 | 108.82% | 摩根士丹利 | →$18 | 開始承保 | →等重 |
| 07/19/2021 | 120.42% | 摩根大通 | →$19 | 開始承保 | →中性 |
| 07/19/2021 | 74.01% | 沃爾夫研究 | →$15 | 開始承保 | →對等性能 |
| 07/19/2021 | 317.63% | 高盛 | →$36 | 開始承保 | →購買 |
| 07/19/2021 | 155.22% | 加拿大皇家銀行資本 | →$22 | 開始承保 | →跑贏大盤 |
| 07/19/2021 | 85.61% | 花旗集團 | →$16 | 開始承保 | →中性 |
| 07/19/2021 | 178.42% | 派珀·桑德勒 | →$24 | 開始承保 | →超重 |
What is the target price for Bright Health Gr (BHG)?
Bright Health Gr(BHG)的目標價格是多少？
The latest price target for Bright Health Gr (NYSE: BHG) was reported by Morgan Stanley on August 30, 2023. The analyst firm set a price target for $8.00 expecting BHG to fall to within 12 months (a possible -7.19% downside). 11 analyst firms have reported ratings in the last year.
光明健康Gr(紐約證券交易所代碼：BHG)的最新目標價是由摩根士丹利於2023年8月30日報道的。這家分析公司將目標價定為8.00美元，預計必和必拓將在12個月內跌至(可能下跌7.19%)。過去一年，有11家分析公司公佈了評級。
What is the most recent analyst rating for Bright Health Gr (BHG)?
分析師對Bright Health Gr(BHG)的最新評級是多少？
The latest analyst rating for Bright Health Gr (NYSE: BHG) was provided by Morgan Stanley, and Bright Health Gr maintained their underweight rating.
光明健康Gr(紐約證券交易所股票代碼：BHG)的最新分析師評級由摩根士丹利提供，光明健康Gr維持其減持評級。
When is the next analyst rating going to be posted or updated for Bright Health Gr (BHG)?
Bright Health Gr(BHG)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bright Health Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bright Health Gr was filed on August 30, 2023 so you should expect the next rating to be made available sometime around August 30, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Bright Health Gr的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Bright Health Gr的上一次評級是在2023年8月30日提交的，所以你應該預計下一次評級將在2024年8月30日左右提供。
Is the Analyst Rating Bright Health Gr (BHG) correct?
分析師對Bright Health Gr(BHG)的評級正確嗎？
While ratings are subjective and will change, the latest Bright Health Gr (BHG) rating was a maintained with a price target of $160.00 to $8.00. The current price Bright Health Gr (BHG) is trading at is $8.62, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的光明健康Gr(BHG)評級保持不變，目標價在160.00美元至8美元之間。Bright Health Gr(BHG)目前的股價為8.62美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。